Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Ensysce Biosciences Inc (ENSCW)

Ensysce Biosciences Inc (ENSCW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ENSCW with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0121 +228.93%
on 04/29/24
0.0450 -11.56%
on 04/11/24
+0.0098 (+32.67%)
since 04/01/24
3-Month
0.0013 +2,961.54%
on 02/13/24
0.0889 -55.23%
on 02/29/24
+0.0248 (+165.33%)
since 02/01/24
52-Week
0.0012 +3,216.67%
on 01/23/24
0.0889 -55.23%
on 02/29/24
+0.0298 (+298.00%)
since 05/01/23

Most Recent Stories

More News
Ensysce Biosciences Announces Positive Bioequivalence (BE) Study Data of Novel "TAAP" Opioid PF614 and Provides Timing of Corporate Update Call

~ BE Study of PF614 Represents Critical Progress Toward FDA Approval ~~ Supports the 505(b)(2) Regulatory Path for Clinical Development of PF614 ~SAN DIEGO, CA / ACCESSWIRE / July 27, 2022 / Ensysce Biosciences,...

ENSC : 0.5690 (-6.41%)
ENSCW : 0.0398 (+41.64%)
Ensysce Biosciences Announces Initial Patients Dosed of First Human Abuse Potential Study

~ Trial Designed to Test and Confirm Nasal Opioid Manipulation ~

ENSC : 0.5690 (-6.41%)
ENSCW : 0.0398 (+41.64%)
Ensysce Biosciences Secures $8 Million Convertible Note Financing

~ Additional Funding from Investor Cohort Validates Company's Mission ~

ENSC : 0.5690 (-6.41%)
ENSCW : 0.0398 (+41.64%)
Ensysce Biosciences Receives Notice of Award for 4th Year of Funding for Its Multi-Pill Abuse Resistance (MPAR(TM)) Platform

SAN DIEGO, CA / ACCESSWIRE / June 27, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve...

ENSC : 0.5690 (-6.41%)
ENSCW : 0.0398 (+41.64%)
Ensysce Biosciences Receives Notice of Award for 4th Year of Funding for Its Multi-Pill Abuse Resistance (MPAR(TM)) Platform

SAN DIEGO, CA / ACCESSWIRE / June 27, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve...

ENSC : 0.5690 (-6.41%)
ENSCW : 0.0398 (+41.64%)
Ensysce Biosciences Reminds Shareholders to Vote At Upcoming 2022 Virtual Annual Shareholder Meeting

- Shareholder Meeting to be Held on Thursday, June 23rd at 9:00 AM PT

ENSC : 0.5690 (-6.41%)
ENSCW : 0.0398 (+41.64%)
Ensysce Biosciences Announces Initiation of First Human Abuse Potential Study

~ Nasal Opioid Abuse Being Explored for PF614 ~

ENSC : 0.5690 (-6.41%)
ENSCW : 0.0398 (+41.64%)
Ensysce Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results

Corporate Update Call to be Held Tuesday, May 17, 2022 SAN DIEGO, CA / ACCESSWIRE / May 12, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage...

ENSC : 0.5690 (-6.41%)
ENSCW : 0.0398 (+41.64%)
Ensysce Biosciences Releases 2021 Annual Shareholder Letter

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

ENSC : 0.5690 (-6.41%)
ENSCW : 0.0398 (+41.64%)
Ensysce Biosciences Announces New Clinical Results from Trials PF614-102 and PF614-MPAR-101

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

ENSCW : 0.0398 (+41.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.0398
2nd Resistance Point 0.0398
1st Resistance Point 0.0398
Last Price 0.0398
1st Support Level 0.0398
2nd Support Level 0.0398
3rd Support Level 0.0398

See More

52-Week High 0.0889
Fibonacci 61.8% 0.0554
Fibonacci 50% 0.0450
Last Price 0.0398
Fibonacci 38.2% 0.0347
52-Week Low 0.0012

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar